Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Daily News

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

Caitlin E. Cox

October 16, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Daily News

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

L.A. McKeown

September 16, 2019

News Daily News

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Caitlin E. Cox

August 12, 2019

News Daily News

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Caitlin E. Cox

July 30, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Daily News

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

Todd Neale

June 03, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Conference News ISET 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

Advertisement

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Microvascular Disease Quadruples Risk of Leg Amputation

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Supervised Exercise Plus Angioplasty Best for Intermittent Claudication: Meta-analysis

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content